Evidence map›Paper›PMID 33440835›Full record

ArticleCancers2021

FAM188B Downregulation Sensitizes Lung Cancer Cells to Anoikis via EGFR Downregulation and Inhibits Tumor Metastasis In Vivo.

Eun-Ju Jang, Jee Young Sung, Ha-Eun Yoo, Hyonchol Jang, Jaegal Shim, Eok-Soo Oh, Sung-Ho Goh, Yong-Nyun Kim

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eun-Ju JangNational Cancer Center, Division of Translational Science, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.
Jee Young SungNational Cancer Center, Division of Translational Science, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.
Ha-Eun YooNational Cancer Center, Division of Translational Science, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.
Hyonchol JangNational Cancer Center, Division of Cancer Biology, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.ORCID 0000-0003-1436-457X
Jaegal ShimNational Cancer Center, Division of Translational Science, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.
Eok-Soo OhDepartment of Life Sciences, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 120-750, Korea.
Sung-Ho GohNational Cancer Center, Precision Medicine Branch, Division of Precision Medicine, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.ORCID 0000-0001-8617-7680
Yong-Nyun KimNational Cancer Center, Division of Translational Science, 323 Ilsan-ro, Ilsandong-gu, Gyeonggi-do, Goyang-si 10408, Korea.
National Cancer Center · KREwha Womans University · KR

Funding

National Cancer Center, Korea 1810082 and 1810291National Research Foundation (NRF) grant funded by Korea government 2020R1A2C100886111
6 · The paper itself

Abstract

Anoikis is a type of apoptosis induced by cell detachment from the extracellular matrix (ECM), which removes mislocalized cells. Acquisition of anoikis resistance is critical for cancer cells to survive during circulation and, thus, metastasize at a secondary site. Although the sensitization of cancer cells to anoikis is a potential strategy to prevent metastasis, the mechanism underlying anoikis resistance is not well defined. Although family with sequence similarity 188 member B (FAM188B) is predicted as a new deubiquitinase (DUB) member, its biological function has not been fully studied. In this study, we demonstrated that FAM188B knockdown sensitized anoikis of lung cancer cell lines expressing WT-EGFR (A549 and H1299) or TKI-resistant EGFR mutant T790M/L858R (H1975). FAM188B knockdown using si-FAM188B inhibited the growth of all three human lung cancer cell lines cultured in both attachment and suspension conditions. FAM188B knockdown resulted in EGFR downregulation and thus decreased its activity. FAM188B knockdown decreased the activities of several oncogenic proteins downstream of EGFR that are involved in anoikis resistance, including pAkt, pSrc, and pSTAT3, with little changes to their protein levels. Intriguingly, si-FAM188B treatment increased EGFR mRNA levels but decreased its protein levels, which was reversed by treatment with the proteasomal inhibitor MG132, indicating that FAM188B regulates EGFR levels via the proteasomal pathway. In addition, cells transfected with si-FAM188B had decreased expression of FOXM1, an oncogenic transcription factor involved in cell growth and survival. Moreover, FAM188B downregulation reduced metastatic characteristics, such as cell adhesion, invasion, and migration, as well as growth in 3D culture conditions. Finally, tail vein injection of si-FAM188B-treated A549 cells resulted in a decrease in lung metastasis and an increase in mice survival in vivo. Taken together, these findings indicate that FAM188B plays an important role in anoikis resistance and metastatic characteristics by maintaining the levels of various oncogenic proteins and/or their activity, leading to tumor malignancy. Our study suggests FAM188B as a potential target for controlling tumor malignancy.

Indexed as

anoikisEGFRFAM188B

Identifiers

PMID33440835
PMCPMC7826942
OpenAlexW3119361502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.